To examine trimester-specific associations among glycemic variability, fetal growth, and birthweight in pregnancies with type 1 diabetes mellitus (Type 1 DM).
Methods:
In this retrospective cohort study of 41 pregnant women with Type 1 DM, we used continuous glucose monitoring (CGM) data to calculate glycemic variability (coefficient of variation of glucose) over a 7-day interval in each trimester. Clinical data, including fetal biometry, birthweight, and perinatal complications, were extracted from medical records.
Results:
Women maintained good glycemic control during pregnancy, with mean HbA1c in the first, second, and third trimester 6.5%, 6.1%, and 6.4%, respectively. Sixty-three percent of infants were large for gestational age (LGA). Estimated fetal weight percentile (EFW%ile) and abdominal circumference percentile (AC%ile) increased during pregnancy, consistent with accelerated prenatal growth. Correlations between trimester-specific glycemic variability and EFW, AC, and birthweight were not statistically significant. After maternal age adjustment, glycemic variability was not associated with birthweight for any trimester (adj. β for first trimester: −38.46, 95% CI: −98.58 to 21.66; adj. β for second trimester: −12.20, 95% CI: −51.47 to 27.06; adj. β for third trimester: −26.26, 95% CI: −79.52 to 27.00).
Conclusions:
The occurrence of LGA remains very high in contemporary U.S. women with Type 1 DM, despite the use of CGM and overall good glycemic control. Neither HbA1c nor glycemic variability predicted fetal overgrowth or birthweight. Since LGA is a key driver of maternal and newborn complications in pregnancies with Type 1 DM, our data emphasize the importance of investigating both glucose-dependent and glucose-independent underlying mechanisms.
Get full access to this article
View all access options for this article.
References
1.
EversIM, de ValkHW, MolBW, et al.: Macrosomia despite good glycaemic control in Type I diabetic pregnancy; results of a nationwide study in The Netherlands. Diabetologia, 2002; 45:1484–1489.
2.
PerssonM, PasupathyD, HansonU, et al.: Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study. Diabetes Care, 2011; 34:1145–1149.
3.
SørensenHT, SabroeS, RothmanKJ, et al.: Relation between weight and length at birth and body mass index in young adulthood: cohort study. BMJ, 1997; 315:1137.
4.
ChiavaroliV, GianniniC, D'AdamoE, et al.: Insulin resistance and oxidative stress in children born small and large for gestational age. Pediatrics, 2009; 124:695–702.
5.
KuchlbauerV, VogelM, GauscheR, et al.: High birth weights but not excessive weight gain prior to manifestation are related to earlier onset of diabetes in childhood: “accelerator hypothesis” revisited. Pediatr Diabetes, 2014; 15:428–435.
6.
LawGR, GilthorpeMS, SecherAL, et al.: Translating HbA1c measurements into estimated average glucose values in pregnant women with diabetes. Diabetologia, 2017; 60:618–624.
7.
LawGR, EllisonGT, SecherAL, et al.: Analysis of CGM in pregnant women with diabetes: distinct temporal patterns of glucose associated with LGA infants. Diabetes Care, 2015; 38:1319–1325.
8.
GuptaR, KhouryJ, AltayeM, et al.: Glycemic excursions in type 1 diabetes in pregnancy: a semiparametric statistical approach to identify sensitive time points during gestation. J Diabetes Res, 2017; 2017:2852913.
9.
McGrathRT, GlastrasSJ, SeehoSK, et al.: Association between glycemic variability, HbA1c, and large-for-gestational-age neonates in women with type 1 diabetes. Diabetes Care, 2017; 40:e98–e100.
10.
FeigDS, DonovanLE, CorcoyR, et al.: CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet, 2017;pii: S0140-6736(17)32400-5. [Epub ahead of print]; DOI: 10.1016/S0140-673632400-5.
11.
KitzmillerJL, BlockJM, BrownFM, et al.: Managing preexisting diabetes for pregnancy. Diabetes Care, 2008; 31:1060–1079.
12.
WilliamsRL, CreasyRK, CunninghamGC, et al.: Fetal growth and perinatal viability in California. Obstet Gynecol, 1982; 59:624–632.
13.
HadlockFP, HarristRB, SharmanRS, et al.: Estimation of fetal weight with the use of head, body and femur measurements—a prospective study. Am J Obstet Gynecol, 1985; 151:333–337.
14.
WHO Child Growth Standards: 2006 World Health Organization. https://www.cdc.gov/growthcharts/who_charts.htm (accessed March1, 2018).
15.
OkenE, KleinmanKP, Rich-EdwardsJ, et al.: A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr, 2003; 3:6.
16.
DasS, IrigoyenM, PattersonMB, et al.: Neonatal outcomes of macrosomic births in diabetic and non-diabetic women. Arch Dis Child Fetal Neonatal Ed, 2009; 94:F419–F422.
17.
GilleanJR, CoonrodDV, RussR, et al.: Big infants in the neonatal intensive care unit. Am J Obstet Gynecol, 2005; 192:1948–1953.
18.
LandonMB, MintzMC, GabbeSG: Sonographic evaluation of fetal abdominal growth: predictor of the large-for-gestational-age infant in pregnancies complicated by diabetes mellitus. Am J Obstet Gynecol, 1989; 160:115–121.
19.
LangerO, KozlowskiS, BrustmanL: Abnormal growth patterns in diabetes in pregnancy: a longitudinal study. Isr J Med Sci, 1991; 27:516–523.
20.
LadforsL, ShaatN, WibergN, et al.: Fetal overgrowth in women with type 1 and type 2 diabetes mellitus. PLoS One, 2017; 12:e0187917.
21.
PedersenJ: Weight and length at birth of infants of diabetic mothers. Acta Endocrinol (Copenh), 1954; 16:330–342.
22.
LandonMB, GabbeSG, PianaR, et al.: Neonatal morbidity in pregnancy complicated by diabetes mellitus: predictive value of maternal glycemic profiles. Am J Obstet Gynecol, 1987; 156:1089–1095.
23.
’Jovanic-PetersonL, PetersonCM, ReedGF, et al.: Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development: Diabetes in Early Pregnancy Study. Am J Obstet Gynecol, 1991; 164 (1 Pt 1):103–111.
24.
James-ToddT, CohenA, WengerJ, et al.: Time-specific placental growth factor (PIGF) across pregnancy and infant birth weight in women with preexisting diabetes. Hypertens Pregnancy, 2016; 35:436–446.
25.
NelsonSM, CoanPM, BurtonGJ, et al.: Placental structure in type 1 diabetes: relation to fetal insulin, leptin and IGF-1. Diabetes, 2009; 58:2634–2641.
26.
IciekR, Wender-OzegowskaE, MikolajczakP, et al.: Placental vascular endothelial growth factor expression in pregnancies complicated by type 1 diabetes. J Physiol Pharmacol, 2014; 65:577–583.
27.
DubovaEA, PavlovKA, EsayanRM, et al.: Vascular endothelial growth factor and its receptors in the placenta of women with type 1 diabetes mellitus. Bull Exp Biol Med, 2012; 152:367–370.
28.
HigginsMF, RussellNE, CrosseyPA, et al.: Maternal and fetal placental growth hormone and IGF axis in type 1 diabetic pregnancy. PLoS One, 2012; 7:e29164.
29.
PerssonM, PasupathyD, HansonU, et al.: Pre-pregnancy body mass index and the risk of adverse outcomes in type 1 diabetic pregnancies: a population-based cohort study. BMJ Open, 2012; 2:e000601.
30.
NielsonGL, DethlefsenC, MøllerM, et al.: Maternal glycated haemoglobin, pre-gestational weight, pregnancy weight gain and risk of large-for-gestational-age babies: a Danish cohort study of 209 singleton Type 1 diabetic pregnancies. Diabet Med, 2007; 24:384–387.
31.
SandlerV, ReisetterAC, BainJR, et al.: HAPO Study Cooperative Research Group. Associations of maternal BMI and insulin resistance with the maternal metabolome and newborn outcomes. Diabetologia, 2017; 60:518–530.
32.
LekvaT, RolandMCP, MichelsenAE, et al.: Large reduction in adiponectin during pregnancy is associated with large-for-gestational-age newborns. J Clin Endocrinol Metab, 2017; 102:2552–2559.
33.
Lazo-de-la-Vega-MonroyML, González-DomínguezMI, ZainaS, et al.: Leptin and its receptors in human placenta of small, adequate, and large for gestational age newborns. Horm Metab Res, 2017; 49:350–358.
34.
IciekR, Wender-OzegowskaE, ZawiejskaA, et al.: Placental leptin and its receptor genes expression in pregnancies complicated by type 1 diabetes. J Physiol Pharmacol, 2013; 64:579–585.
35.
KosK, SynWK, LewandowskiKC, et al.: Comparison of maternal ghrelin and leptin in healthy mothers and mothers with Type 1 diabetes. Diabet Med, 2008; 25:1400–1405.
36.
NelsonSM, SattarN, FreemanDJ, et al.: Inflammation and endothelial activation is evident at birth in offspring of mothers with type 1 diabetes. Diabetes, 2007; 56:2697–2704.
37.
DitchfieldAM, DesforgesM, MillsTA, et al.: Maternal obesity is associated with a reduction in placental taurine transporter activity. Int J Obes (Lond), 2015; 39:557–564.
38.
MatulevicieneV, JosephJI, AndelinM, et al.: A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian real-time system) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technol Ther, 2014; 16:759–767.
39.
KropffJ, BruttomessoD, DollW, et al.: Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab, 2015; 17:343–349.
